Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ALIOFNASDAQ:CDXCNASDAQ:CRONOTCMKTS:STDAF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALIOFALIOF$278.50$278.50$138.01▼$286.30$29.89BN/A924 shsN/ACDXCChromaDex$6.16$2.31▼$9.18$611.50M2.21780,463 shs554,788 shsCRONCronos Group$2.03-1.0%$1.85$1.60▼$2.69$790.08M1.061.30 million shs1.29 million shsSTDAFSTADA Arzneimittel Aktiengesellschaft$110.42$110.42$75.15▼$115.00$6.88B0.38180 shsN/A12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALIOFALIOF0.00%0.00%0.00%0.00%0.00%CDXCChromaDex0.00%0.00%0.00%+45.11%+148.11%CRONCronos Group0.00%-5.14%+9.73%+3.05%-27.24%STDAFSTADA Arzneimittel Aktiengesellschaft0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALIOFALIOFN/AN/AN/AN/AN/AN/AN/AN/ACDXCChromaDex2.8379 of 5 stars3.50.00.04.00.00.01.9CRONCronos Group0.9572 of 5 stars0.03.00.00.03.30.01.3STDAFSTADA Arzneimittel AktiengesellschaftN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALIOFALIOF 0.00N/AN/AN/ACDXCChromaDex 3.00Buy$9.03∞ UpsideCRONCronos Group 0.00N/AN/AN/ASTDAFSTADA Arzneimittel Aktiengesellschaft 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ALIOF, STDAF, CRON, and CDXC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/17/2025CDXCChromaDexHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.003/10/2025CDXCChromaDexHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$8.00 ➝ $11.003/5/2025CDXCChromaDexLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$6.80 ➝ $8.10(Data available from 5/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALIOFALIOFN/AN/AN/AN/AN/AN/ACDXCChromaDex$99.60M0.00N/AN/A$0.38 per share0.00CRONCronos Group$124.59M6.28N/AN/A$2.87 per share0.71STDAFSTADA Arzneimittel Aktiengesellschaft$3.84B1.79$11.12 per share9.93$23.11 per share4.78Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALIOFALIOFN/AN/A0.00∞N/AN/AN/AN/AN/ACDXCChromaDex-$4.94M$0.10787.290.00N/A1.62%4.85%2.70%N/ACRONCronos Group-$73.96M$0.13N/A67.671.74-42.65%-2.56%-2.47%N/ASTDAFSTADA Arzneimittel Aktiengesellschaft$292.15MN/A0.00∞N/AN/AN/AN/AN/ALatest ALIOF, STDAF, CRON, and CDXC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025CRONCronos Group$0.01$0.02+$0.01$0.02$45.44 million$33.62 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALIOFALIOFN/AN/AN/AN/AN/ACDXCChromaDexN/AN/AN/AN/AN/ACRONCronos GroupN/AN/AN/AN/AN/ASTDAFSTADA Arzneimittel AktiengesellschaftN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALIOFALIOFN/AN/AN/ACDXCChromaDexN/A2.952.35CRONCronos GroupN/A24.2423.05STDAFSTADA Arzneimittel Aktiengesellschaft2.231.540.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALIOFALIOFN/ACDXCChromaDex15.41%CRONCronos Group8.71%STDAFSTADA Arzneimittel AktiengesellschaftN/AInsider OwnershipCompanyInsider OwnershipALIOFALIOFN/ACDXCChromaDex9.64%CRONCronos Group7.30%STDAFSTADA Arzneimittel AktiengesellschaftN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALIOFALIOFN/A107.33 millionN/ANot OptionableCDXCChromaDex12077.75 million69.02 millionOptionableCRONCronos Group450385.41 million356.14 millionOptionableSTDAFSTADA Arzneimittel Aktiengesellschaft12,50062.34 millionN/ANot OptionableALIOF, STDAF, CRON, and CDXC HeadlinesRecent News About These CompaniesFor Faculty & StaffOctober 10, 2024 | smith.eduChicago's GTCR in advanced talks to acquire German drugmakerSeptember 10, 2024 | chicagobusiness.comTrump calls his former chief of staff a ‘terrible, stupid person’August 29, 2024 | msnbc.comStada CEO confirms company may be for saleAugust 6, 2024 | pharmaphorum.comThis week’s deal pipeline: Bain and Cinven consider IPO option for Stada ArzneimittelMay 18, 2024 | penews.comAJMC StaffMay 8, 2024 | ajmc.comWDBJ7 StaffApril 22, 2024 | wdbj7.comSTAFF NEWSFebruary 22, 2024 | washingtonpost.comKPLUY K+S AktiengesellschaftJanuary 10, 2024 | seekingalpha.comKPLUY K+S AktiengesellschaftJanuary 10, 2024 | seekingalpha.comPopSci StaffNovember 24, 2023 | popsci.comBrighton and Hove council staff to receive more moneySeptember 26, 2023 | theargus.co.ukNCR Editorial StaffSeptember 19, 2023 | ncronline.orgStaff SenateAugust 11, 2023 | uwyo.eduSTADA Arzneimittel AG V (SAZA)July 21, 2023 | investing.comWhy are flags at half-staff today in Wisconsin?June 10, 2023 | jsonline.comCBI hired 'toxic' staff and failed to sack offendersMay 30, 2023 | bbc.co.ukWTVY StaffMay 13, 2023 | wtvy.comStaff EditorialsApril 15, 2023 | thegazette.comBA StaffMarch 29, 2023 | baseballamerica.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALIOF, STDAF, CRON, and CDXC Company DescriptionsALIOF OTCMKTS:ALIOF$278.50 0.00 (0.00%) As of 09/27/2022Actelion Ltd. develops, produces and markets pharmaceutical drugs. The firm engages in research, development, manufacturing, and distribution of pharmaceutical, biological, and diagnostic products. The company was founded by Jean-Paul Clozel, Martine Clozel, Walter Fischli, André J. Müller and Thomas Widmann on December 30, 1999 and is headquartered in Allschwil, Switzerland.ChromaDex NASDAQ:CDXCChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.Cronos Group NASDAQ:CRON$2.03 -0.02 (-0.98%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$2.03 0.00 (0.00%) As of 05/23/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.STADA Arzneimittel Aktiengesellschaft OTCMKTS:STDAF$110.42 0.00 (0.00%) As of 10/24/2022STADA is a publicly traded, international company with a focus on the healthcare market, especially the pharmaceutical and in particular the generics market. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Trade Desk Silences Critics; Recovery Looks Poised to Continue Alphabet Stock Lags—But Waymo May Be Its Hidden Driver This Market Sell-Off Might Trigger a Value Rotation Into Pepsi Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
